KR101020680B1 - 4차 켈리도닌 및 알칼로이드 유도체류, 그들의 제조방법 및약제 제조에서의 그들의 용도 - Google Patents

4차 켈리도닌 및 알칼로이드 유도체류, 그들의 제조방법 및약제 제조에서의 그들의 용도 Download PDF

Info

Publication number
KR101020680B1
KR101020680B1 KR1020057017086A KR20057017086A KR101020680B1 KR 101020680 B1 KR101020680 B1 KR 101020680B1 KR 1020057017086 A KR1020057017086 A KR 1020057017086A KR 20057017086 A KR20057017086 A KR 20057017086A KR 101020680 B1 KR101020680 B1 KR 101020680B1
Authority
KR
South Korea
Prior art keywords
derivative
krs
reaction product
alkylating agent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057017086A
Other languages
English (en)
Korean (ko)
Other versions
KR20060010726A (ko
Inventor
바실 노비키
Original Assignee
바실 노비키
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바실 노비키 filed Critical 바실 노비키
Publication of KR20060010726A publication Critical patent/KR20060010726A/ko
Application granted granted Critical
Publication of KR101020680B1 publication Critical patent/KR101020680B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
KR1020057017086A 2003-03-18 2004-03-12 4차 켈리도닌 및 알칼로이드 유도체류, 그들의 제조방법 및약제 제조에서의 그들의 용도 Expired - Fee Related KR101020680B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03006015A EP1459753A1 (en) 2003-03-18 2003-03-18 Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments
EP03006015.6 2003-03-18

Publications (2)

Publication Number Publication Date
KR20060010726A KR20060010726A (ko) 2006-02-02
KR101020680B1 true KR101020680B1 (ko) 2011-03-09

Family

ID=32798820

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057017086A Expired - Fee Related KR101020680B1 (ko) 2003-03-18 2004-03-12 4차 켈리도닌 및 알칼로이드 유도체류, 그들의 제조방법 및약제 제조에서의 그들의 용도

Country Status (36)

Country Link
US (1) US7795434B2 (enExample)
EP (2) EP1459753A1 (enExample)
JP (1) JP5303719B2 (enExample)
KR (1) KR101020680B1 (enExample)
CN (1) CN1532198A (enExample)
AR (1) AR043629A1 (enExample)
AT (1) ATE469651T1 (enExample)
AU (1) AU2004222661B2 (enExample)
BR (1) BRPI0408386A (enExample)
CA (1) CA2517769C (enExample)
CL (2) CL2004000552A1 (enExample)
CY (1) CY1112598T1 (enExample)
DE (1) DE602004027496D1 (enExample)
DK (1) DK1644012T3 (enExample)
EA (1) EA009049B1 (enExample)
ES (1) ES2346216T3 (enExample)
GE (1) GEP20084501B (enExample)
GT (1) GT200400046A (enExample)
HR (1) HRP20050987B1 (enExample)
IL (1) IL170505A (enExample)
MA (1) MA27833A1 (enExample)
MX (1) MXPA05009919A (enExample)
MY (1) MY141779A (enExample)
NO (1) NO333672B1 (enExample)
NZ (1) NZ542151A (enExample)
PA (1) PA8598201A1 (enExample)
PE (1) PE20050351A1 (enExample)
PL (1) PL1644012T3 (enExample)
PT (1) PT1644012E (enExample)
SG (1) SG158748A1 (enExample)
SI (1) SI1644012T1 (enExample)
TN (1) TNSN05230A1 (enExample)
TW (1) TWI347939B (enExample)
UA (1) UA89353C2 (enExample)
WO (1) WO2004082698A1 (enExample)
ZA (1) ZA200507020B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
CN102552264A (zh) * 2012-02-28 2012-07-11 苏州大学 血根碱在制备电离辐射防护剂中的应用
WO2021073603A1 (en) * 2019-10-17 2021-04-22 Chengdu Anticancer Bioscience, Ltd. Benzophenanthridine alkaloids and their methods of use
CN113372355B (zh) * 2021-05-13 2023-02-17 山东大学 六氢苯并菲啶类生物碱及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865830A (en) 1969-06-16 1975-02-11 Nikolai Mikhailovich Turkevich Thiophosphamide derivatives of isoquinoline alkaloids, method of producing and application thereof
SU368254A1 (ru) 1969-06-16 1973-01-26 А. И. Потопальский , В. М. Новицкий Львовский государственный медицинский институт Способ получения соединений тиофосфамида с алкалоидами чистотела большого
AT354644B (de) 1975-12-19 1980-01-25 Nowicky Wassili Verfahren zur herstellung von neuen salzen von alkaloidderivaten von thiophosphorsaeure
AT377988B (de) 1976-06-28 1985-05-28 Nowicky Wassili Verfahren zur herstellung von neuen phosphorderivaten von alkaloiden
DE3128018A1 (de) 1981-07-13 1983-04-07 Wassyl 1060 Wien Nowicky "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
US4970212A (en) 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
AT407833B (de) * 1995-06-01 2001-06-25 Nowicky Wassyl Dr Mittel zur behandlung von strahlenschäden
AT408719B (de) 2000-03-22 2002-02-25 Nowicky Wassili Mittel zur behandlung von hepatitis c
CH695417A5 (de) 2001-11-15 2006-05-15 Ddr Wassyl Nowicky Dipl Ing Verfahren zur Umsetzung von Alkaloiden.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PHYTOCHEMISTRY, PERGAMON, PRESS, GB, vol. 44, no. 2, pp 257-266, 1997.01.
PLANTA MEDICA, THIEME, STUTTGART, DE, vol.67, no. 2, pp 108-113, 2001

Also Published As

Publication number Publication date
TNSN05230A1 (en) 2007-06-11
NO20054130D0 (no) 2005-09-06
CA2517769A1 (en) 2004-09-30
CL2004000552A1 (es) 2005-01-21
GT200400046A (es) 2005-11-24
US7795434B2 (en) 2010-09-14
EP1644012B1 (en) 2010-06-02
NO333672B1 (no) 2013-08-05
EA200501473A1 (ru) 2006-02-24
TW200505467A (en) 2005-02-16
JP5303719B2 (ja) 2013-10-02
AR043629A1 (es) 2005-08-03
GEP20084501B (en) 2008-10-10
JP2006520763A (ja) 2006-09-14
EP1644012A1 (en) 2006-04-12
PA8598201A1 (es) 2004-11-26
US20060154947A1 (en) 2006-07-13
DE602004027496D1 (de) 2010-07-15
AU2004222661A1 (en) 2004-09-30
MY141779A (en) 2010-06-30
UA89353C2 (uk) 2010-01-25
CY1112598T1 (el) 2016-02-10
PL1644012T3 (pl) 2011-01-31
PE20050351A1 (es) 2005-05-04
DK1644012T3 (da) 2010-10-04
ATE469651T1 (de) 2010-06-15
EP1459753A1 (en) 2004-09-22
BRPI0408386A (pt) 2006-03-21
AU2004222661B2 (en) 2008-10-02
KR20060010726A (ko) 2006-02-02
HRP20050987A2 (en) 2007-07-31
CL2008002345A1 (es) 2009-01-02
TWI347939B (en) 2011-09-01
CA2517769C (en) 2012-09-25
ZA200507020B (en) 2006-11-29
CN1532198A (zh) 2004-09-29
HRP20050987B1 (hr) 2014-03-28
NO20054130L (no) 2005-12-19
EA009049B1 (ru) 2007-10-26
WO2004082698A1 (en) 2004-09-30
SI1644012T1 (sl) 2010-10-29
NZ542151A (en) 2008-11-28
MA27833A1 (fr) 2006-04-03
IL170505A (en) 2013-04-30
PT1644012E (pt) 2010-07-29
ES2346216T3 (es) 2010-10-13
MXPA05009919A (es) 2006-03-21
SG158748A1 (en) 2010-02-26

Similar Documents

Publication Publication Date Title
CN108379591B (zh) 免疫激动剂靶向化合物的合成及其应用
CZ2001479A3 (cs) Vodorozpustné proléky bráněných alkoholů nebo fenolů
CN113845551B (zh) 一种具有光动力抗三阴乳腺癌活性的Pt(Ⅱ)配合物及其制备方法和应用
KR101020680B1 (ko) 4차 켈리도닌 및 알칼로이드 유도체류, 그들의 제조방법 및약제 제조에서의 그들의 용도
ES2201136T3 (es) Preparaciones terapeuticas de quasinoides con actividad antineoplasica, antiviral y herbistatica.
RU2120939C1 (ru) 6-[x-(2-гидроксиэтил)аминоалкил]-5,11-диоксо-5,6-дигидро-11h-инде- но/1,2-с/изохинолины или их соли с неорганическими и органическими кислотами, способы их получения и фармацевтическая композиция на их основе
WO1996014065A9 (en) Therapeutic quassinoid preparations with antineoplastic, antiviral, and herbistatic activity
CN114667288A (zh) 苯并菲啶生物碱及其使用方法
JP2006520763A5 (enExample)
CA2593202A1 (en) Quaternary alkaloid derivatives of chelidonium majus l
TWI308569B (en) Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents
US7732485B2 (en) Treatment of cancer
FI75802C (fi) Foerfarande foer framstaellning av saosom immunostimulerande aemnen anvaendbara bis- och polydisulfider.
JP2002535276A (ja) ４−デメチルペンクロメジンのアシル誘導体、その使用及び調製
SE437931B (sv) Lekemedelspreparat med antitumorverkan innehallande fosfat av polyhexametylenguanidin med angiven formel
HK1066530A (en) Quaternary chelidonine derivatives
CN118976022A (zh) 桑辛素的抗淋巴瘤用途
CN120682279A (zh) 一种具有光动力断裂DNA能力的ICD诱导剂Ru(II) 配合物及其制备方法和应用
KR100634232B1 (ko) 항암활성을 갖는 신규한 화합물과 그 제조방법 및 상기화합물을 함유하는 항암활성 의약 조성물
KR100891943B1 (ko) 신규 오보바톨 유도체 또는 이의 약학적으로 허용가능한염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 치료및 예방용 약학적 조성물
CN112279860A (zh) 一种芳香胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用
CN112279861A (zh) 一种烷基胺取代的斑蝥素衍生物及其制备方法、其药物组合物及其应用
CN107266353A (zh) 一类新型1－氨基－2－羟基－3－四氢咔唑－丙烷类化合物及其抗肿瘤用途
KR20120105739A (ko) 3,4-디히드로퀴나졸린 이염산염 및 그를 포함하는 항암제 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140303

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150506

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180303

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180303